The cleanest way to read Mexico’s medical-device industry in 2026 is not as a manufacturing story. It is a regulatory story, a tariff story, and an OEM-concentration story stacked on top of a manufacturing base that has been quietly compounding for fifty years. Medtronic opened its first Tijuana facility in 1970. By the time most observers noticed, the cluster was already the largest medical-device manufacturing concentration in North America by employment. Three things changed materially in 2025. The first was a regulatory reform that compressed COFEPRIS approval timelines by a factor of six for FDA-cleared devices. The second was the activation of Section 232 metal tariffs that hit the cluster on the input side rather than the output side. The third was a new wave of investment — Intuitive Surgical, Abbott, BD, Medline — that brought higher-complexity programs into Mexico for the first time at scale.
The cluster is bigger than people realize
Baja California is the anchor. The state hosts roughly 100 medical-device companies — 73 of them in Tijuana — employing approximately 100,000 workers directly, with another 250,000 households dependent on the sector indirectly. Direct employment in the cluster grew from 77,000 to 100,000 in three years, with eight new greenfield investments arriving between January 2024 and January 2025 alone. Tijuana exports roughly $3 billion annually; the broader Baja California cluster generates more than $7 billion — about 70% of national medical-device exports. The cluster runs at 89% capacity utilization. By any reasonable measure, this is one of the most concentrated, mature, and active precision-manufacturing corridors in the Western Hemisphere.
The OEM density is what makes the cluster substantive. Medtronic operates two Tijuana facilities employing 11,500 people who manufacture 18 million devices per year, including hand-stitched cardiovascular valves, TAVI replacement valves, and pediatric cardiac devices for “blue babies” — every Global 7500 of cardiac care has a Mexican-built component in it. Stryker runs a 300,000-square-foot manufacturing hub with over 1,000 employees making endoscopy accessories and reprocessed single-use surgical devices. Becton Dickinson operates 12 plants in Mexico with 17,000 employees, including a Cuautitlán Izcalli site that produces 55% of all BD pre-filled glass syringes globally and a soon-to-open $80 million sterilization plant in Ciudad Juárez. Welch Allyn manufactures diagnostic instruments and thermometers. Cardinal Health, Edwards Lifesciences, ResMed, Smith & Nephew, Johnson & Johnson, Siemens Healthineers, DJO Global (2,000+ employees), Fisher & Paykel Healthcare (1,500+), Flex (4,300 in its Medical Center of Excellence), Carl Zeiss Vision (3,000), Jabil (2,943), ICU Medical (2,500), Merit Medical (2,100) — the list runs through nearly every name on the AdvaMed top fifty.
“Tijuana sits at the heart of North America’s largest medical device manufacturing cluster. Companies relocating to Tijuana report operational cost savings of 18–25% compared to equivalent US facilities. For a manufacturer with $50 million in annual operating expenses, that is $9–12.5 million redirected toward R&D, regulatory compliance, or market expansion.”
Mexicali is where the cluster’s most interesting recent move happened. On April 24, 2026 — four days before this page went live — Intuitive Surgical inaugurated its third building at the Carranza Campus, a 440,000-square-foot facility that will add 1,500 jobs to the company’s existing 4,700-employee Mexicali operation. Intuitive produces over 95% of the surgical instruments used in the da Vinci robotic-surgery systems deployed in hospitals across more than 70 countries — and that production is concentrated almost entirely in Mexicali. The company’s CEO publicly stated that the operating practices developed in Mexicali are now the model for Intuitive’s manufacturing operations worldwide. This is the single largest signal of the past year that Mexican medical-device manufacturing has moved past “low-cost assembly” and into “anchor program for the world’s most sophisticated medical robotics.”
Ciudad Juárez is the second cluster — 34 companies, 40,000 direct jobs, anchored by BD’s three plants, Johnson & Johnson’s roughly 13,000-person operation focused on Class II and Class III exports, Cardinal Health’s 1,300 workers, Cordis (3,000 employees, cardiac catheters), and Ambu’s largest single-use endoscope plant globally (3,000 employees, 30,000 square meters). Tamaulipas — Reynosa, Matamoros, Nuevo Laredo — adds another 15,000+ jobs across BD, Stanley Black & Decker’s medical operations, and recent arrivals including Fresenius Medical Care, which shifted 309 dialysis-manufacturing jobs from Concord, California to Reynosa during 2025.
The newer story is in the Bajío. Abbott Laboratories inaugurated a $200 million electrophysiology manufacturing plant in Querétaro in January 2026 — the company’s CEO Robert Ford personally attended. The site begins with cardiac mapping and imaging catheters and will scale to ablation catheters by phase two, with workforce projected to grow from 300 employees today to over 1,200 by the end of the decade. Querétaro hosts 57 active investment projects worth roughly MX$75 billion ($3.75 billion) in the pipeline, of which Abbott is the highest-profile medical-device entry. The Sonora cluster — Hermosillo, Guaymas, Empalme — accommodates 26 companies and 17,240 specialized workers focused on TE Connectivity Medical, Nordson Medical, and Haemonetics programs. Saltillo, Coahuila has 54 companies and 60,000 system-wide manufacturing jobs across diversified life sciences. Guadalajara hosts 52 medical-technology corporations specializing in cross-sector electronic convergence and sterile packaging.
The 30-day fast lane that opened in September 2025
The most material change to the sector in 2025 was not a tariff or an investment — it was a regulatory reform. On September 1, 2025, COFEPRIS (Mexico’s federal health regulator, equivalent to the US FDA) launched the Vía Regulatoria Abreviada — Abbreviated Regulatory Pathway — that compresses device-registration timelines from six-plus months to a target of 30 business days for products already approved by recognized international regulators.
The mechanism is equivalency. COFEPRIS now formally recognizes approvals issued by the US FDA (510(k), De Novo, or PMA), Health Canada (Medical Device License), Japan’s PMDA, the European Medicines Agency under EU MDR, Swissmedic, Australia’s TGA, and the broader IMDRF / MDSAP framework. Manufacturers submit a summary technical dossier rather than a full repeat technical package, and COFEPRIS targets a 30-business-day review window. The framework was published in the Diario Oficial de la Federación on July 18, 2025, with operational reforms cascading through August 22 and October 6, 2025. It is part of Plan México, the Sheinbaum administration’s industrial-modernization agenda.
The implementation is not yet frictionless. Several Mexican regulatory advisory firms have noted that COFEPRIS systems and electronic platforms are still being adapted to the new homoclaves (procedural codes), and actual review windows in late 2025 and early 2026 have varied by dossier complexity. The headline 30-day target is real, but manufacturers planning a Mexican domestic launch should build buffer into the timeline through 2026.
The reform also aligns Mexico with NOM-241-SSA1-2012 — the local Good Manufacturing Practice standard — which is already satisfied by ISO 13485 certification through equivalency. Roughly 70% of medical-device facilities in Mexico already operate Class 10,000 and Class 100,000 cleanrooms, are routinely audited by FDA QSIT, and hold MDSAP certifications. The regulatory infrastructure was already in place; September 2025 is when the policy framework caught up to the manufacturing reality.
Tariffs hit medical devices differently — and the input side is the real story
The line that matters most for medical devices is not the same as the one that matters for autos. USMCA Chapter 90 — which governs medical devices, optical instruments, and precision equipment — sets a Regional Value Content threshold of 60% via the Transaction Value method or 50% via Net Cost. That is meaningfully lower than the automotive chapter’s 75% (with a proposed 85% under the joint-review investigation), and most Class I and Class II medical devices clear the threshold without supply-chain restructuring.
The IEEPA fentanyl tariffs imposed in February 2025 explicitly exempted USMCA-compliant goods effective March 7, 2025. The Section 122 surcharge that took effect February 24, 2026 carries broad medical-device exemptions for civil products and USMCA-compliant entries. The output side of the tariff stack — Mexico-to-US flows of finished medical devices — is structurally protected.
The pressure is on the input side. The June 2025 expansion of Section 232 to 50% tariffs on imported steel and aluminum (with country-of-origin smelt provisions reducing the rate to 10% only when 95%+ US-origin can be documented) hits Mexican medical-device manufacturers on the materials they import to build devices. The 50% Section 232 rate compounds with Mexico’s own tariff increases on textiles, steel, aluminum, and specialty alloys imposed across 2025-2026 to comply with North American supply-chain verification requirements. The President of the Baja California Medical Device Cluster, Rosa Castañeda, publicly stated in March 2026 that “Mexican tariffs on materials are hurting us more than US tariffs” — naming textiles (specialized woven and braided structures used in implants), steel, and aluminum as the three most exposed inputs.
This creates a counterintuitive cost picture: a Mexican medical-device manufacturer exporting to the US under USMCA captures the cluster’s labor-cost advantage and avoids the 50% Section 232 metal duty on the finished device — but pays the duty on the metal components imported to build that device, plus Mexican-side input tariffs on the same materials. The cluster is currently building a five-year supplier-development plan to localize input sourcing. Industry estimates put the time to certify a new Mexican-side specialty supplier at three to ten years, depending on the regulatory complexity of the end product. That timeline does not match the speed at which tariff policy is currently moving.
The composite read on 2026: the regulatory environment got materially friendlier in September 2025, the output-tariff environment remains the friendliest in major manufacturing, and the input-tariff environment is the constraint that nobody is solving fast enough. For most product lines this is a manageable trade-off. For specialty programs heavily dependent on imported polymers, Tyvek packaging, or textile structures used in implantables, the input-side math should be re-run before any 2026 capacity decisions.